Articles tagged "Adverse effects"

2015 American Transplant Congress
Safety and Outcome of Ganciclovir-Resistant CMV Treated With Foscarnet: A Single Center Retrospective Study
B. Pierce,⁴ C. Richardson,⁴ K. Cunningham,⁴ C. D'Agostino,⁴ C. Tseng,⁴ J. Brown,⁴ C. O'Brien,⁴ B. Ho,^1,3,5 M. Ison.^1,2,3
¹Department of Medicine, Northwestern Medicine, Chicago, IL; ²Division of Infectious Diseases, Northwestern Medicine, Chicago, IL; ³Division of Organ Transplantation, Northwestern Medicine, Chicago, IL; ⁴Pharmacy, Northwestern Medicine, Chicago, IL; ⁵Transplant Nephrology, Northwestern Medicine, Chicago, IL.
Background: Infection with cytomegalovirus (CMV) is an important cause of morbidity and mortality following solid organ transplantation (SOT). Resistance can rarely develop via mutations in…
2015 American Transplant Congress
Clinically Relevant Wound Events With Everolimus-Based Immunosuppressive Regimen: Post-Hoc Analysis from a Randomized Heart Transplant Study
A. Zuckermann,¹ M. Rinaldi,¹ N. Yonan,¹ S.-S. Wang,¹ G. Dong,² P. Lopez.²
¹For the A2309 Study Group, Vienna, Austria; ²Novartis, Basel, Switzerland.
Purpose: In the A2310 (NCT00300274) heart transplant (HTx) study with everolimus (EVR) vs mycophenolate mofetil (MMF), information on a broad spectrum of potential wound healing…
2015 American Transplant Congress
Alemtuzumab Induction Has Been Safe in the United Kingdom and Achieves Long-Term Steroid Avoidance in More Than 80% of Low Risk Renal Transplant Recipients
A. Seitz,¹ M. Robb,³ S. Balasubramanian,¹ A. McLean,² D. Taube,² R. Johnson,³ R. Baker.¹
¹Renal Unit, St. James's Hospital, Leeds, United Kingdom; ²West London Renal and Transplant, Hammersmith Hospital, London, United Kingdom; ³Organ Donation and Transplantation Studies, NHS Blood and Transplant, Bristol, United Kingdom.
Introduction: The use of alemtuzumab as an induction agent for renal transplantation is increasing in the UK. There is some evidence to suggest that this…
2015 American Transplant Congress
Associations of Pre-Transplant Prescription Narcotic Use With Clinical Complications After Kidney Transplantation
N. Lam,¹ M. Schnitzler,² J. Tuttle-Newhall,² H. Xiao,² D. Axelrod,³ D. Brennan,⁴ V. Dharnidharka,⁴ M. Nazzal,² K. Lentine.²
¹Western University, London, ON, Canada; ²Saint Louis University, St. Louis, MO; ³Dartmouth Hitchcock Medical Center, Hanover, NH; ⁴Washington University School of Medicine, St. Louis, MO.
Background: Associations of narcotic use before kidney transplantation with post-transplant clinical outcomes are not well described.Methods: We performed a retrospective analysis of linked national registry…
2015 American Transplant Congress
Adverse Events of Maintenance Immunosuppression Following Kidney Transplantation Reported in Randomized Controlled Trials: A Systematic Review
M. Howell,^1,2 R. Yeo,² A. Tong,^1,2 J. Craig,^1,2 K. Howard,² G. Wong.^2,3
¹Centre for Kidney Research, The Children's Hospital at Westmead, Westmeand, NSW, Australia; ²School of Public Health, University of Sydney, Sydney, NSW, Australia; ³Centre for Transplant and Renal Research, Westmead Hospital, Westmead, NSW, Australia.
Aim: To evaluate the completeness of reporting of adverse events in randomized controlled trials (RCTs) of maintenance immunosuppression in kidney transplantation.Background: Side effects of maintenance…
2015 American Transplant Congress
Quality of Life, Financial, and Mental Health Outcomes for Individuals Turned Down for Live Kidney Donation
P. Reese,¹ C. Carney,¹ S. Levsky,¹ R. Pendse,¹ D. Leidy,¹ A. Mussell,¹ R. Bloom,¹ M. Allen,¹ D. Collins,¹ S. Keddem,¹ P. Abt,¹ J. Rodrigue,² E. Emanuel.¹
¹UPenn, Philadelphia, PA; ²Harvard, Cambridge, MA.
Introduction: Individuals considering live kidney donation should have a thorough understanding of the risks and benefits. Regulations focus exclusively on donation risks. However, no data…
2015 American Transplant Congress
Effect of Antibody Mediated Rejection on Long-Term Renal Allograft Function
M. John, A. Smith, I. Dortonne, A. Paramesh, M. Killackey, B. Lee, R. Zhang, J. Buell.
Transplant Institute, Tulane University, New Orleans, LA.
Historically we had poor understanding of chronic rejection attributing it to hypertension and non-compliance. However in the last decade we have begun to understand the…
2015 American Transplant Congress
De Novo Once-Daily Tacrolimus in Liver Transplantation: Long-Term Outcomes of a Single Center Cohort of 150 Patients
M. Gastaca, A. Valdivieso, J. Bustamante, P. Ruiz, J. Fernandez, A. Ventoso, M. Testillano, I. Palomares, P. Salvador, M. Prieto, A. Matarranz, M. Suarez, J. Ortiz de Urbina.
Liver Transplantation Unit, Cruces University Hospital. University of the Basque Country, Bilbao, Vizcaya, Spain.
Purpose: To describe the long-term safety and efficacy profile of de novo once-daily tacrolimus (Tac QD) in orthotopic liver transplantation (OLT)Patients and methods: A retrospective…
2015 American Transplant Congress
Tacrolimus Trough Concentrations Increase in Intestinal Transplant Recipients During Episodes of Acute Cellular Rejection
A. Lichvar,¹ D. Deen,² H. Johnson,¹ J. Bonner,³ G. Bond,⁴ G. Costa,⁴ R. Cruz,⁴ K. Abu-Elmagd,⁵ R. Venkataramanan.^6,7
¹Department of Pharmacy and Therapeutics, University of Pittsburgh Medical Center, Pittsburgh, PA; ²Department of Pharmacy, Memorial University Medical Center, Savannah, GA; ³Northern Institute for Cancer Research at Newcastle University, Tyne and Wear, United Kingdom; ⁴Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA; ⁵Center for Gut Rehabilitation and Transplantation, Cleveland Clinic, Cleveland, OH; ⁶Thomas E. Starzl Transplantation Institute, University of Pittsburgh Medical Center, Pittsburgh, PA; ⁷Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA.
Introduction: Acute cellular rejection (ACR) in small bowel transplant recipients is expected to increase intestinal permeability and to reduce intestinal CYP3A/p-glycoprotein activity. These changes may…